Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis

Paused · Phase 2 · Has a placebo group

Conditions studied: Psoriasis

In brief

The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.

Key facts

Study ID

NCT01368887

Run by

DermiPsor, Ltd.

People needed

160

Starts

2013-04-01

Expected to finish

2014-04-01

Last updated by the study team

2011-06-08

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Male or female of age 18 or older
• Patient with a personal history of scalp psoriasis
• Patient with treatable lesions
• Patient with a TSS score equal or lower than 9.
• Patient with a PGA score equal or lower than 5.
• Patient with a negative urine pregnancy test at inclusion for women of childbearing potential and using an efficient contraceptive (oral contraceptives, IUD, or tubal ligation)
• Patient agreeing to participate to the study and to sign a written informed consent and comply with study requirements.

You may not qualify if…

• Patient treated with topical scalp treatment for scalp psoriasis within two weeks prior to the inclusion in the study (corticoids, retinoids, vitamin D derivatives),
• Patient treated with systemic treatment for psoriasis (biologics, methotrexate, cyclosporine, retinoids) within one month prior to the inclusion in the study
• Patient taking systemic niacin or multivitamins within past two weeks
• Patient who start or modify a treatment with beta-blockers within one month prior to the inclusion in the study
• Patient with PEG (Poly Ethylene Glycol) allergy
• Pregnant or breast feeding female or female who do not use contraception,
• Patient with an history of hypersensitivity to Dovonex/Daivonex
• Patient who has participated in a clinical trial within three month prior inclusion,
• Patients on Carbamazepine and Primidione (the clearance of Primidione and Carbamazepine may be reduced with the concomitant use of Nicotinamide)
• Patient who is under guardianship, or unable to understand the information (for linguistic or mental reason), or unwilling to give her/his informed consent to participate in the study

Where it is running

• Boston VA Hospital — Boston, Massachusetts, United States
• Brockton VA Hospital — Brockton, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.